Clinical Trials Finder

Independent ClinicalTrials.gov directory

Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 6:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 110 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Human Epidermal Growth Factor 2 Negative Carcinoma of Breast Clear all

Completed Phase 1 Interventional

A Study of ZN-c5 in Participants With Breast Cancer

NCT04176757

View directory record Official record

Conditions: Breast Cancer
Interventions: ZN-c5; Drug
Lead sponsor: Zeno Alpha Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 5
States / cities: Tucson, Arizona • New York, New York • Nashville, Tennessee + 2 more

Source: ClinicalTrials.gov public record

Updated Jul 31, 2022 · Synced May 21, 2026, 6:24 PM EDT

Terminated Phase 2 Interventional Results available

Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer

NCT01394211

View directory record Official record

Conditions: Estrogen Receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Male Breast Cancer, Recurrent Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
Interventions: anastrozole, pazopanib hydrochloride, therapeutic conventional surgery; Drug · Procedure
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older

Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Tucson, Arizona

Source: ClinicalTrials.gov public record

Updated Jul 25, 2018 · Synced May 21, 2026, 6:24 PM EDT

Completed Phase 2 Interventional Results available

A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery

NCT05549505

View directory record Official record

Conditions: Breast Cancer
Interventions: ARV-471, Anastrozole, Surgical resection of breast tumor; Drug · Procedure
Lead sponsor: Arvinas Inc.; Industry
Eligibility: 18 Years and older · Female only

Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 13
States / cities: Springdale, Arkansas • Los Angeles, California • Torrance, California + 10 more

Source: ClinicalTrials.gov public record

Updated Aug 28, 2025 · Synced May 21, 2026, 6:24 PM EDT

Active, not recruiting Phase 3 Interventional

Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

NCT06760637

View directory record Official record

Conditions: Breast Cancer
Interventions: PF-07220060, letrozole, abemaciclib, palbociclib, ribociclib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older

Enrollment: 1,035 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2037
U.S. locations: 218
States / cities: Birmingham, Alabama • Chandler, Arizona • Gilbert, Arizona + 135 more

Source: ClinicalTrials.gov public record

Updated May 18, 2026 · Synced May 21, 2026, 6:24 PM EDT

Completed No phase listed Observational

TREATMENT AND MONITORING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS RECEIVING PALBOCICLIB COMBINATION TREATMENT (WITH AI OR FULVESTRANT) FOR HR+/HER2- A/MBC IN A COMMUNITY ONCOLOGY SETTING.

NCT04498481

View directory record Official record

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only

Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: New York, New York

Source: ClinicalTrials.gov public record

Updated Feb 26, 2026 · Synced May 21, 2026, 6:24 PM EDT

Completed Phase 1 Interventional

A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer

NCT02684032

View directory record Official record

Conditions: Breast Cancer
Interventions: Gedatolisib, Palbociclib, Letrozole, Fulvestrant; Drug
Lead sponsor: Celcuity Inc; Industry
Eligibility: 18 Years and older · Female only

Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 41
States / cities: Birmingham, Alabama • Corona, California • Fountain Valley, California + 17 more

Source: ClinicalTrials.gov public record

Updated Jul 26, 2022 · Synced May 21, 2026, 6:24 PM EDT

Terminated Phase 3 Interventional Results available

A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients

NCT01905592

View directory record Official record

Conditions: Neoplasms, Breast, Carcinoma of Breast, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Neoplasms
Interventions: niraparib, Physician's choice; Drug
Lead sponsor: Tesaro, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 25
States / cities: Tucson, Arizona • Los Angeles, California • Fort Myers, Florida + 20 more

Source: ClinicalTrials.gov public record

Updated Nov 14, 2022 · Synced May 21, 2026, 6:24 PM EDT

Completed No phase listed Observational Results available

RW Treatment Patterns and Outcomes in Postmenopausal HR+/HER2- mBC Patients Treated With Palbociclib Plus Letrozole as Initial Endocrine Therapy at Community Oncology Practices in the U.S.

NCT04460898

View directory record Official record

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only

Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: New York, New York

Source: ClinicalTrials.gov public record

Updated Oct 3, 2024 · Synced May 21, 2026, 6:24 PM EDT

Recruiting Phase 1 Interventional

RADIANT: Pre-op Radiation With Abemaciclib and Letrozole

NCT06139107

View directory record Official record

Conditions: Breast Cancer
Interventions: Abemaciclib, Letrozole; Drug
Lead sponsor: Mridula George, MD; Other
Eligibility: 60 Years and older · Female only

Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 4
States / cities: Belleville, New Jersey • Livingston, New Jersey • New Brunswick, New Jersey + 1 more

Source: ClinicalTrials.gov public record

Updated Nov 13, 2025 · Synced May 21, 2026, 6:24 PM EDT

Completed Phase 1 Interventional

HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer

NCT03685331

View directory record Official record

Conditions: Metastatic Breast Cancer, Locally Advanced Breast Cancer, Advanced Breast Cancer, BRCA2 Mutation, BRCA1 Mutation
Interventions: Palbociclib, Olaparib, Fulvestrant; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older · Female only

Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Source: ClinicalTrials.gov public record

Updated Jan 8, 2026 · Synced May 21, 2026, 6:24 PM EDT

Recruiting Phase 3 Interventional

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

NCT06982521

View directory record Official record

Conditions: PIK3CA Mutation, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer
Interventions: RLY-2608, Capivasertib, Fulvestrant; Drug
Lead sponsor: Relay Therapeutics, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 51
States / cities: Gilbert, Arizona • Beverly Hills, California • Duarte, California + 41 more

Source: ClinicalTrials.gov public record

Updated May 7, 2026 · Synced May 21, 2026, 6:24 PM EDT

Active, not recruiting Phase 3 Interventional Results available

Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

NCT04915755

View directory record Official record

Conditions: Neoplasms, Breast
Interventions: Niraparib, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older

Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 24
States / cities: Burbank, California • Duarte, California • Palo Alto, California + 20 more

Source: ClinicalTrials.gov public record

Updated Jul 15, 2025 · Synced May 21, 2026, 6:24 PM EDT

Recruiting Phase 3 Interventional

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

NCT06058377

View directory record Official record

Conditions: Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma
Interventions: Biospecimen Collection, Cyclophosphamide, Doxorubicin, Durvalumab, Genetic Testing, Mammography, Paclitaxel, Quality-of-Life Assessment; Procedure · Drug · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older

Enrollment: 3,680 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 534
States / cities: Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 411 more

Source: ClinicalTrials.gov public record

Updated May 19, 2026 · Synced May 21, 2026, 6:24 PM EDT

Active, not recruiting Phase 3 Interventional

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

NCT04895358

View directory record Official record

Conditions: Breast Neoplasms
Interventions: pembrolizumab, paclitaxel, nab-paclitaxel, liposomal doxorubicin, capecitabine, normal saline, dextrose; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older

Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 41
States / cities: Birmingham, Alabama • Tucson, Arizona • Monterey, California + 33 more

Source: ClinicalTrials.gov public record

Updated Mar 10, 2026 · Synced May 21, 2026, 6:24 PM EDT

Withdrawn Phase 4 Interventional

A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer

NCT03988114

View directory record Official record

Conditions: Metastatic Breast Cancer
Interventions: Abemaciclib, Nonsteroidal Aromatase Inhibitor (NSAI); Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older

Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 70
States / cities: Daphne, Alabama • Tempe, Arizona • Fountain Valley, California + 60 more

Source: ClinicalTrials.gov public record

Updated Sep 5, 2019 · Synced May 21, 2026, 6:24 PM EDT

Recruiting Phase 1 Interventional

BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer

NCT06756932

View directory record Official record

Conditions: Hormone-receptor-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer
Interventions: BGB-21447, Fulvestrant, BGB-43395; Drug
Lead sponsor: BeOne Medicines; Industry
Eligibility: 18 Years and older

Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 4
States / cities: Newport Beach, California • Iowa City, Iowa • Houston, Texas + 1 more

Source: ClinicalTrials.gov public record

Updated Nov 9, 2025 · Synced May 21, 2026, 6:24 PM EDT

Recruiting Not applicable Interventional

Impact of Intermittent Fasting on Biomarkers of Inflammation and Health-Related Quality of Life: A Feasibility Trial for Women With HR+/HER2- Early Breast Cancer

NCT06106477

View directory record Official record

Conditions: Breast Cancer
Interventions: Intermittent Fasting; Behavioral
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older

Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Source: ClinicalTrials.gov public record

Updated Aug 12, 2025 · Synced May 21, 2026, 6:24 PM EDT

Terminated Phase 2 Interventional Results available

Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy

NCT00759642

View directory record Official record

Conditions: Metastatic Breast Cancer
Interventions: lapatinib; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older · Female only

Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 3
States / cities: Kansas City, Kansas • Topeka, Kansas • Kansas City, Missouri

Source: ClinicalTrials.gov public record

Updated Jun 30, 2019 · Synced May 21, 2026, 6:24 PM EDT

Active, not recruiting Phase 2 Interventional

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

NCT06105632

View directory record Official record

Conditions: Advanced or Metastatic Breast Cancer
Interventions: PF-07220060 CDK4 inhibitor, Fulvestrant, Everolimus, Exemestane; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older

Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 17
States / cities: Irvine, California • Los Angeles, California • Newport Beach, California + 9 more

Source: ClinicalTrials.gov public record

Updated Feb 12, 2026 · Synced May 21, 2026, 6:24 PM EDT

Recruiting Phase 2 Interventional

Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer.

NCT07227233

View directory record Official record

Conditions: Breast Cancer
Interventions: A CDK4/6 inhibitor different from the first that the participant had received, plus fulvestrant., Treatment of physician's choice; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older

Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: La Jolla, California

Source: ClinicalTrials.gov public record

Updated Apr 8, 2026 · Synced May 21, 2026, 6:24 PM EDT

Recruiting Phase 1 Interventional

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

NCT06586957

View directory record Official record

Conditions: Solid Tumor, Advanced Solid Tumor, Solid Tumor, Adult, Metastatic Tumor, Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Metastatic Ovarian Carcinoma, Endometrial Neoplasms, Endometrial Diseases, Metastatic Endometrial Cancer, Triple Negative Breast Cancer, Metastatic Endometrial Carcinoma, Advanced Endometrial Carcinoma, Advanced Ovarian Carcinoma, Gastric Cancer, Advanced Gastric Carcinoma, Metastatic Gastric Cancer, Metastatic Gastric Carcinoma, Small Cell Lung Cancer, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms, Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Carcinoma, CCNE1 Amplification, Hormone Receptor Negative Breast Carcinoma, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Progesterone-receptor-positive Breast Cancer
Interventions: NKT3964; Drug
Lead sponsor: NiKang Therapeutics, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 19
States / cities: Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 16 more

Source: ClinicalTrials.gov public record

Updated Apr 20, 2026 · Synced May 21, 2026, 6:24 PM EDT

Active, not recruiting Phase 1Phase 2 Interventional

A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors

NCT05262400

View directory record Official record

Conditions: Breast Cancer, Solid Tumors
Interventions: PF-07220060 + PF-07104091 combination dose escalation, PF-07104091 + PF-07220060 + fulvestrant dose expansion, PF-07104091 + PF-07220060 + letrozole dose expansion; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older

Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 12
States / cities: Los Angeles, California • Santa Monica, California • Boston, Massachusetts + 5 more

Source: ClinicalTrials.gov public record

Updated Nov 17, 2024 · Synced May 21, 2026, 6:24 PM EDT

Completed No phase listed Observational

Estimation of the Prevalence of HER2 Low and Describe the SoC, Treatment Patterns, and Outcome in Real-world Practice Among Unresectable and/or Metastatic Breast Cancer Patients With HER2 Low Status

NCT04807595

View directory record Official record

Conditions: Breast Cancer
Interventions: None (Observational study); Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years

Enrollment: 798 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Source: ClinicalTrials.gov public record

Updated Mar 5, 2023 · Synced May 21, 2026, 6:24 PM EDT

Recruiting Phase 3 Interventional

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

NCT04862663

View directory record Official record

Conditions: Locally Advanced (Inoperable) or Metastatic Breast Cancer
Interventions: Capivasertib, Fulvestrant, Palbociclib, Ribociclib, Abemaciclib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 99 Years

Enrollment: 895 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 52
States / cities: Tucson, Arizona • Fountain Valley, California • Glendale, California + 45 more

Source: ClinicalTrials.gov public record

Updated Apr 19, 2026 · Synced May 21, 2026, 6:24 PM EDT